NEW YORK — Wearable neurotech took two major steps toward the mainstream this month: U.S. regulators cleared the first at-home brain-stimulation headset for depression, and Apple confirmed Vision Pro will support brain-computer interface inputs through its accessibility stack, Dec. 23, 2025.
The FDA approval centers on Flow Neuroscience’s FL-100, a prescription device that delivers transcranial direct current stimulation (tDCS) for adults with moderate to severe major depressive disorder who are not considered treatment-resistant. The agency’s public filing lists the indication and limitations, while reporting has said the company expects a U.S. launch in 2026 and prices in the hundreds of dollars.
Wearable neurotech moves from clinic to couch
Clinicians have long used device-based depression therapies in supervised settings, but the FL-100’s at-home clearance signals a shift toward consumer-like delivery under medical oversight. In the FDA’s summary of safety and effectiveness data, the agency describes the trial foundation for approval and flags uncertainties that come with real-world use, including challenges around blinding in neuromodulation studies.
The clearance also caps a yearslong arc for tDCS as a portable option. A 2020 peer-reviewed review outlined Flow’s headset design and the broader evidence base for home-style protocols, and more recent research has pushed remote, supervised brain-stimulation trials into larger, multisite formats.
Wearable neurotech meets spatial computing
On the consumer-tech side, Apple has said iOS, iPadOS and visionOS will add a new protocol so Switch Control can work with brain-computer interface (BCI) devices—positioning “thought-driven” input as an accessibility pathway rather than a mainstream interface, at least at first. Apple has said Apple’s announcement did not brand Vision Pro as medical hardware, but it did frame BCI compatibility as a way to help users with severe mobility disabilities control devices without physical movement. Apple’s accessibility update suggests the company is laying plumbing that third-party neurotech firms can plug into.
This fits a longer continuity line in implantable BCIs: Synchron announced its first human U.S. implant in 2022, while Neuralink disclosed its Neuralink disclosed its first human implant in early 2024—milestones that helped push “BCI” from lab shorthand into household vocabulary. Synchron’s 2022 U.S. implant announcement and Reuters’ 2024 report on Neuralink’s first implant underscored how quickly the space has moved from feasibility to early adoption.
Privacy risks loom as brain signals become data
As wearable neurotech scales, the most durable fight may be about governance: what counts as “neural data,” who owns it, and how it can be shared or monetized. Policy researchers have warned that brain-related signals can be unusually revealing, creating privacy and security challenges that look different from typical health metrics. New America’s analysis of neurotech privacy risks outlines why consent, retention and secondary use can be harder to police when inputs are tied to cognition and mental state.
Those concerns are increasingly political. Earlier this year, senators urged the Federal Trade Commission to scrutinize neurotech companies over how they collect and share brain data, pointing to gaps for products that sit outside medical-device rules. The Verge’s report on the FTC push highlighted how fast consumer-facing neurotechnology is outpacing privacy norms.
For now, the near-term story is practical: a depression device cleared for home use, and a major platform vendor standardizing how BCIs can talk to headsets and screens. But as wearable neurotech spreads beyond clinics and trials, the industry’s next approvals may hinge as much on data handling as on electrodes and algorithms. For coverage of the FDA clearance and what it allows, see the agency’s listing for the FL-100 approval record, as well as reporting on the rollout and cost expectations.
